AB0058 Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis

Abstract

patients in both groups were recorded and results were compared both within and between the groups. Results Significant improvements were observed in both groups in morning stiffness, joint pain, Ritchie articular index, serum CRP and ESR levels compared to values before treatment, beginning from first month to sixth month (p < 0.001). In the functional assessment; significant improvements were observed in both, determined beginning from the first month to sixth month compared to before treatment both in group receiving a night dose prednisolone and morning dose prednisolone (p < 0.05). In comparison of morning stiffness, joint pain, Ritchie articular index and its functional assessment, and serum CRP and ESR levels in both groups, no significant difference was obtained from first month to sixth month (p > 0.05). Conclusion Low dose prednisolone therapy in treatment of RA significantly suppresses the activity of disease beginning from the first month. This condition is kept until the sixth month. However, administration of the medication either given at morning hours classically or at night according to the diurnal rhythym of disease activity doesn?t affect the results of the treatment.

RETRACTED ARTICLE: Safety and effectiveness of high-dose methotrexate (over 8 mg/week) in 2838 Japanese patients with rheumatoid arthritis: A postmarketing surveillance report

“…[10,11], low-dose MTX clinical trials, and prior postmarketing studies (data on file). In an assessment conducted previously including spontaneous reports in Japan, a majority of patients with RA who died due to hematopoietic disorders received MTX doses of <6 mg/week at the time of onset of the ADR, were older (!70 years), and were associated with renal disorders (Pfizer Japan Inc., Rheumatrex Proper Use Information, Vol.20, 2014, Vol 22,.…”

A Case Report of Acute Toxicity of Methotrexate

“…[3] In another study, 284 RA patients treated with MTX were followed up for a mean of 33.2 months. [6] In this study 14patients (4.9%) had gastrointestinal side effects, nine patients(3.1%) had increased liver enzymes, six patients (2.1%) had interstitial pneumonia and four patients (1.4%) developed pancytopenia. Nadir and Şencan [5] have reported a case of febrile neutropenia and pancytopenia that developed during MTX treatment (7.5 mg/week, for 3 years).…”

Patterns of Cytopenias Associated with Methotrexate Treated Rheumatoid Arthritis Patients

“…It has proved to be efficacious for patients of RA and is a preferred choice of rheumatologists worldwide. 6,7 It has certain adverse effects, which may be troublesome for the patients in the short and long term. Its effect on blood counts has been observed with great concern among all the adverse effects.…”